SWAP-70 Inhibitor Screening for Causal IgE Allergy Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current allergy treatments are largely symptomatic and do not address the root cause of IgE production, leading to inefficiencies and side effects, with existing inhibitors like omalizumab intercepting rather than stopping IgE production and potentially triggering allergic reactions.
Innovation Solution
A method to screen for active ingredients that inhibit SWAP-70, which positively regulates IgE production by modulating the interaction between STAT-6 and BCL-6, allowing for the development of causal therapies for allergies and autoimmune diseases by specifically targeting IgE production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If omalizumab is used to treat allergies, then IgE-mediated allergic reactions are reduced, but IgE production is not stopped and new allergic reactions may be triggered
Solution Approach 1:
The patent applies preliminary action by developing compounds that prevent IgE production before it occurs, rather than intercepting IgE after production. The screenable compounds inhibit the IgE production pathway upstream, blocking the formation of IgE antibodies in the first place, which eliminates the risk of reactions to therapeutic antibodies while maintaining treatment effectiveness
Solution Approach 2:
The patent uses small molecule compounds as intermediaries that target the IgE production pathway. These small molecules act as mediators between the therapeutic goal and the biological system, inhibiting key enzymes or proteins involved in IgE synthesis without requiring large protein therapeutics, thus avoiding immunogenicity issues
2Object-affected harmful factors
If current symptomatic treatments are used, then allergic symptoms are alleviated, but the root cause of IgE production is not addressed
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism responsible for IgE production. By identifying and inhibiting key proteins or enzymes in the IgE production pathway using screenable compounds, the treatment addresses the root cause rather than just symptoms, while the compounds can be optimized for specificity and efficacy
Solution Approach 2:
The patent employs screenable compounds that modify parameters in the IgE production pathway, such as inhibiting enzyme activity or blocking protein-protein interactions. This changes the biological parameters controlling IgE synthesis, shifting the system from a symptomatic treatment approach to a causal therapy that fundamentally alters the disease mechanism
3Reliability
If antibody therapies are used to inhibit IgE, then allergic reactions are reduced, but the therapy is pharmacologically complex to produce and may trigger immune reactions
Solution Approach 1:
The patent replaces complex, expensive monoclonal antibody therapies with small molecule compounds that are simpler to produce and administer. These small molecules can be synthesized through established pharmaceutical processes, reducing manufacturing complexity and cost while maintaining therapeutic effectiveness through targeted inhibition of IgE production
Solution Approach 2:
The patent substitutes the mechanical/structural complexity of large protein therapeutics with simpler small molecule compounds. By using screenable small molecules that target specific molecular interactions in the IgE pathway, the therapy replaces the need for complex antibody production and administration with simpler chemical entities that can be orally administered or given via standard routes
Data Source
Figure 1A~1C
Figure 2A~2C
Figure 3
AI summary
The invention relates to the field of biomedical and pharmacological research, in particular to the area of immunology, allergies and autoimmune diseases. The inventors have shown that SWAP-70 is a higher-level regulator for STAT-6 and BCL-6, the regulator being specific for IgE production in B-cells by amplifying the effect of STAT-6 and antagonizing the effect of BCL-6. The inventors have observed no influence of SWAP-70 on the expression of other genes that are likewise regulated by STAT-6 and/or BCL-6. In summary, it can be concluded that SWAP-70 positively regulates IgE production by shifting the interaction of the two antagonists STAT-6 and BCL-6 with regulatory elements of the IgE gene in favor of the activator STAT-6. Based on said findings, the invention provides a screening method which allows for identifying novel active agents that specifically inhibit IgE production. The substances identified by the method according to the invention are particularly suited for treating IgE-induced allergies and IgE-dependent autoimmune diseases.